CAR T Therapy Shows Similar Efficacy, Safety in Multiple Myeloma Subgroups
Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.
Related Articles
PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer
Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.
BESPOKE: ctDNA Clearance During and After ACT
Panelists discuss how circulating tumor DNA (ctDNA) clearance rates during and after adjuvant chemotherapy (ACT) in the BESPOKE trial provide critical insights into treatment efficacy…
What inspires oncology nurses to choose cancer care?
Oncology nurses discuss what inspired them to dedicate their careers to cancer care and research at Ohio State.
Gene Assay Can Guide Chemo Strategies in Older Breast Cancer Population
The use of chemotherapy trended toward improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Promising Treatment To Raise the Standard of Care in Lower-Risk MDS-Related Anemia
CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
Elraglusib Plus Chemo Enhances Survival Vs Chemo Alone in Metastatic PDAC
A survival benefit was noted when elraglusib was added to chemotherapy for patients with metastatic PDAC.
Rechallenge With RET Inhibitors Shows Efficacy in Pretreated NSCLC
RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.
Six or More Cycles of Chemo Prolong Survival With Atezolizumab in ES-SCLC
The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.
Pembrolizumab/Cisplatin and RT Enhance Responses in Unresectable Vulvar Cancer
For patients with unresectable vulvar cancer, an improved ORR was observed with pembrolizumab plus cisplatin and RT, followed by maintenance pembrolizumab.
Sevabertinib Exhibits Activity in Treatment-Naïve HER2-Mutant NSCLC
Among 2 patient subgroups with advanced, HER2-mutant non–small cell lung cancer, sevabertinib showed comparable objective response rates.